Connect your AI

Johnson & Johnson JNJ Accounts Receivable

Accounts Receivable at other companies

AbbottABT

$8.21B+12.1%

Bristol-Myers SquibbBMY

$9.37B-13.3%

Tenet HealthcareTHC

$2.47B+0.2%

PfizerPFE

$12.59B+6.2%

Procter & GamblePG

$6.32B+3.0%

Merck & Co.MRK

$12.21B+13.2%

Other financials

Income statement

Revenue$24.1B+9.9%

Gross profit$16.0B+9.8%

Operating income$6.3B+2.3%

Net income$5.2B-52.4%

EPS (diluted)$2.14-52.9%

Balance sheet

Cash & equivalents$21.7B-43.6%

Total debt$55.0B+5.2%

Total equity$81.2B+3.9%

Total assets$200.89B+3.7%

Cash flow

Operating cash flow$2.5B-39.8%

CapEx$1.0B+31.9%

Free cash flow$1.5B-56.6%

Valuation

Market cap$623.71B+66.9%

Enterprise value$657.01B+61.9%

P/E29.6×+13.2×

P/S6.5×+2.3×

Profitability

Gross margin67.8%-0.5pp

Operating margin26.4%+2.8pp

Net margin21.8%-2.6pp

FCF margin18.5%-4.3pp

Returns & leverage

Return on equity26.4%-3.0pp

Debt / equity0.7×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Johnson & Johnson's accounts receivable?: Johnson & Johnson (JNJ) reported accounts receivable of $17.72B in Q1 2026.
How has Johnson & Johnson's accounts receivable changed year-over-year?: Johnson & Johnson's accounts receivable increased by 10.6% year-over-year, from $16.02B to $17.72B.
What is the long-term trend for Johnson & Johnson's accounts receivable?: Over 5 years (2020 to 2025), Johnson & Johnson's accounts receivable has grown at a 4.8% compound annual growth rate (CAGR), from $13.58B to $17.18B.
What does accounts receivable mean?: Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.